SUBJECT INDEX SI15
antisocial personality disorder
vs., 594–595
symptoms of, 594f
treatment of, 597–599
Psychopharmacology, 111–114
Psychosexual stages, 18–19
Psychosis, 6
amphetamine, 392–393
Freud on, 19
from LSD, 414
Psychosocial problems
DSM-IV-TR classifi cation of,
80–81
Psychosocial therapies/
treatments, 117
Psychotic disorders, 519–565.
See also Schizophrenia
defi nition of, 520
delirium vs., 691
differentiagnosis of, 533f
not otherwise specifi ed, 84
Psychotic features, 196–197
Psychotropic medications, 111
Punishment, 50–52
in behavior therapy, 125
conduct disorder and, 651,
662
Purging, 439, 440, 443
° Q °Qi, 11–12
Quality of life, 110
in avoidant personality
disorder, 614
Quasi-experiments, 159–160,
167t
Questionnaires, 171–172
° R °Racial/ethnic groups
alcohol use in, 404, 411
avoidant personality disorder
and, 615
bipolar disorders and, 221
clinical assessment and, 96,
104t
cognitive distortions and, 55
dependent personality
disorder and, 617
diagnostic bias and, 76–77
discrimination against, 64
dissociative disorders in, 333
dissociative fugue in, 338,
339–340
eating disorders and, 451
eating disorders in, 457
high expressed emotion in,
61, 61f
patient/therapist match in,
186
in personality disorders, 593
personality disorders and,
583
placebo effects and, 186–187
schizophrenia and, 551
social exclusion and, 206
social phobia and, 284
substance use disorders and,
386, 389–390
symptom differences in, 174
treatment issues with, 143–147
Random assignment, 159, 167
Randomized clinical trials
(RCTs), 181–184
Rape, sadistic, 487
Rapid cycling, 221
Rapid eye movement (REM)
sleep, 194, 271
Rational-emotive behavior
therapy (REBT), 128–129,
128f
Rationalization, 20f
Rational Recovery, 429
Razadyne, 711
Reaction formation, 20f
Reactive interaction, 46–47
Reactivity, 173–174
Reading disorder, 643, 644
Reagan, Ronald, 723
Reality orientation therapy,
711–712
REBT. See Rational-emotive
behavior therapy (REBT)
Recall, 683–684
Receptors, chemical, 41
Recessive genes, 43
Reciprocal-gene–environment
model, 45
Recovered memories, 349
Refeeding syndrome, 463
Refractory period, 495, 495f
Reframing, 138
Rehabilitation, 698
Rehnquist, William, 385
Reiland, Rachel, 567–568, 574,
577, 579, 592, 599–600,
608, 617, 621–622
Reinforcement, 50, 51t
in behavior therapy, 125
Reinforcers, 50
Rejection, sensitivity to, 280
Relapse
in eating disorders, 468
in pedophilia, 486
in schizophrenia, 550–551,
557
in substance use disorders,
421, 422, 740–741
Relapse prevention training, 493
Relaxation training
for eating disorders, 465
for panic disorder, 273
for posttraumatic stress
disorder, 323–324
Reliability, 77–78, 89, 101, 372
Relief cravings, 400
Religion
avoidant personality disorder
and, 615
dissociation in, 332–333
in obsessive-compulsive
disorder, 306
suicide and, 235, 238
Remeron, 211, 286Reminiscence therapy, 712
Rennie v. Klein, 739
Reporting bias, 96–97
Repression, 20f
Research, 153–189
case studies in, 163–164
challenges in, 169–174
confi dentiality in, 719
correlational, 160–163, 166t
dropouts in, 176–177
ethics in, 167–168
exclusion criteria in, 173
experiments in, 156–159,
166t
informed consent in, 720–721
meta-analysis in, 166, 166t
on neurological factors,
169–170
on psychological factors,
170–172
quasi-experimental, 159–160,
166t
scientifi c method in, 153–168
single-participant, 164–166,
166t
on social factors, 172–174
on treatment, 175–188
types of, 156–167
Residential treatment, 140, 428,
562
Residual schizophrenia, 528
Resistance, 120
Resistant/anxious attachment,
25
Resolution phase, 495, 495f
Response bias, 171–172, 172f
Response contingencies, 125
Response prevention, exposure
with, 125, 308–309
for eating disorders, 465
Reston, Carolina, 75f
Restrained eating, 454
Restructuring beliefs, 24
Rett’s disorder, 629t, 641
Reuptake, neurotransmitter, 42
Reuptake inhibitors, 113
ReVia, 423
Reward cravings, 400
Reward dependence, 59
in antisocial personality
disorder, 596
Rey Osterrieth Test, 94f
Risk factors, 162–163
Risk of harm, 4–5, 7
Risperidone, 558
Ritalin, 394
Rogers, Carl, 21, 121
Role disputes, 136t, 230
Role-playing, 667
Role transition, 136t
Rorschach, Herman, 100–101
Rorschach test, 100–101
Rouse v. Cameron, 739
Rumination, 203–204, 207
Running syndrome, 338
Rush, Benjamin, 15° S °
S-adenosyl-L-methionine
(SAMe), 211
Sadism, sexual, 483t, 486–487
Safe people, 271
Samples, 159
Sampling bias, 159
Schizoaffective disorder, 529,
530, 534, 534t
Schizoid personality disorder,
583–585
Asperger’s disorder vs., 637
Schizophrenia, 519–565, 534t
aging and, 686
borderline personality
disorder vs., 602
brain ventricles in, 90, 90f
catatonic, 541
cognitive defi cits in, 524–525
defi cit/nondefi cit subtypes of,
528
defi nition of, 520
delirium vs., 691
dementia vs., 703–704
diagnosis of, 74
diagnostic bias in, 76
disorganized, 527
DSM-IV-TR diagnostic
criteria for, 82t, 525–526
family functioning and, 102
feedback loops in, 553–555,
554f, 563–565, 563f
frontal lobe abnormalities
in, 36
genetics in, 43
heritability of, 45
heterogeneity of groups with,
83
high expressed emotion and
relapse in, 61, 61f
medications for, 113
negative symptoms of, 520,
523–524
neurological factors in,
541–547, 556–559
paranoid, 526–527
positive symptoms of,
520–523
prognosis for, 538, 539t
psychological factors in,
547–549, 559–560
research challenges in, 169
residual, 528
schizotypal personality
disorder vs., 587
social factors in, 549–552,
560–562
substance use disorder and,
387–388
symptom course in, 536–537
transcranial magnetic
stimulation for, 170
treatment of, 556–564
undifferentiated, 528
Schizophreniform disorder, 529,
530, 534t